The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Open accessAbstract
BACKGROUND: Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate-mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung. METHODS: In this double-blind, placebo-controlled study, we randomly assigned 278 patients with symptomatic pulmonary arterial hypertension (either idiopathic or associated with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) to placebo or sildenafil (20, 40, or 80 mg) orally three times daily for 12 weeks. The primary end point was the change from baseline to week 12 in the distance walked in six minutes. The change in mean pulmonary-artery pressure and World Health Organization (WHO) functional class and the incidence of clinical worsening were also assessed, but the study was not powered to assess mortality. Patients completing the 12-week randomized study could enter a long-term extension study. RESULTS: The distance walked in six minutes increased from baseline in all sildenafil groups; the mean placebo-corrected treatment effects were 45 m (+13.0 percent), 46 m (+13.3 percent), and 50 m (+14.7 percent) for 20, 40, and 80 mg of sildenafil, respectively (P<0.001 for all comparisons). All sildenafil doses reduced the mean pulmonary-artery pressure (P=0.04, P=0.01, and P<0.001, respectively), improved the WHO functional class (P=0.003, P<0.001, and P<0.001, respectively), and were associated with side effects such as flushing, dyspepsia, and diarrhea. The incidence of clinical worsening did not differ significantly between the patients treated with sildenafil and those treated with placebo. Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m. CONCLUSIONS: Sildenafil improves exercise capacity, WHO functional class, and hemodynamics in patients with symptomatic pulmonary arterial hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationThe 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,069
Clinical classification of pulmonary hypertension
Simonneau, G., Galiè, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.037 · Cited by 1,897
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationPrimary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
Self-citationTreatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Self-citationCellular and molecular pathobiology of pulmonary arterial hypertension
Humbert, M., Morrell, N. W., Archer, S. L., Stenmark, K. R., MacLean, M. R., Lang, I. M., Christman, B. W., Weir, E. K., Eickelberg, O., Voelkel, N. F., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.029 · Cited by 1,576
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Self-citationGiaid, A., & Saleh, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330403 · Cited by 1,369
MIYAMOTO, S., NAGAYA, N., SATOH, T., KYOTANI, S., SAKAMAKI, F., FUJITA, M., NAKANISHI, N., & MIYATAKE, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,154
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
PEPKEZABA, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92033-x · Cited by 1,055
Diagnosis and differential assessment of pulmonary arterial hypertension
Barst, R. J., McGoon, M., Torbicki, A., Sitbon, O., Krowka, M. J., Olschewski, H., & Gaine, S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.032 · Cited by 992
Self-citationMichelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Cyclic GMP Phosphodiesterase-5: Target of Sildenafil
Corbin, J. D., & Francis, S. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13729 · Cited by 531
Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
Ghofrani, H. A., Wiedemann, R., Rose, F., Olschewski, H., Schermuly, R. T., Weissmann, N., Seeger, W., & Grimminger, F. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-7-200204020-00008 · Cited by 496
Self-citationClinical efficacy of sildenafil in primary pulmonary hypertension
Sastry, B. K. S., Narasimhan, C., Reddy, N. K., & Raju, B. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.056 · Cited by 488
Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., & Wilkins, M. R. (2001) · Circulation · doi:10.1161/hc2901.093117 · Cited by 488
Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension
Wilkens, H., Guth, A., König, J., Forestier, N., Cremers, B., Hennen, B., Böhm, M., & Sybrecht, G. W. (2001) · Circulation · doi:10.1161/hc3601.096826 · Cited by 392
Ghofrani, H. A., Rose, F., Schermuly, R. T., Olschewski, H., Wiedemann, R., Kreckel, A., Weissmann, N., Ghofrani, S., Enke, B., Seeger, W., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00555-2 · Cited by 365
Self-citationChronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats
SCHERMULY, R. T., Kreisselmeier, K. P., Ghofrani, H. A., Yilmaz, H., BUTROUS, G. S., Ermert, L., Ermert, M., Weißmann, N., Rose, F., Guenther, A., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200302-282oc · Cited by 256
Self-citationGaliè, N., Seeger, W., Naeije, R., Simonneau, G., & Rubin, L. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.038 · Cited by 255
Self-citationAntiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells
Tantini, B., Manes, A., Fiumana, E., Pignatti, C., Guarnieri, C., Zannoli, R., MD, A. B., & Gali�, N. (2005) · Basic Research in Cardiology · doi:10.1007/s00395-004-0504-5 · Cited by 191
Self-citationPulsed Delivery of Inhaled Nitric Oxide to Patients With Primary Pulmonary Hypertension
Channick, R. N., Newhart, J. W., Johnson, F. W., Williams, P. J., Auger, W. R., Fedullo, P. F., & Moser, K. M. (1996) · Chest · doi:10.1378/chest.109.6.1545 · Cited by 185
Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors
Rabe, K. F., Tenor, H., Dent, G., Schudt, C., Nakashima, M., & Magnussen, H. (1994) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1994.266.5.l536 · Cited by 183
Cohen, A. H., Hanson, K., Morris, K., Fouty, B., McMurty, I. F., Clarke, W., & Rodman, D. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118386 · Cited by 170
Testing strategies in multi-dose experiments including active control
Bauer, P., Röhmel, J., Maurer, W., & Hothorn, L. A. (1998) · Statistics in Medicine · Cited by 163
Dose response studies II. analysis and interpretation
Ruberg, S. J. (1995) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409508835097 · Cited by 124
Bhatia, S., Frantz, R. P., Severson, C. J., Durst, L. A., & McGoon, M. D. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.10.1207 · Cited by 122
Cl- current activation in choroid plexus epithelial cells involves a G protein and protein kinase A
Kotera, T., & Brown, P. D. N. (1994) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1994.266.2.c536 · Cited by 88
The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension
Michelakis, E. D. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7960-5_19 · Cited by 67
The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension
Michelakis, E. D. (2003) · Heart Failure Reviews · doi:10.1023/a:1022150819223 · Cited by 60
Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation
Jernigan, N. L., & Resta, T. C. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00273.2001 · Cited by 46
Multiple Testings: Multiple Comparisons and Multiple Endpoints
Chi, G. Y. H. (1998) · Drug Information Journal · doi:10.1177/00928615980320s131 · Cited by 36
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citation
Metadata
- Authors
- Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., & Simonneau, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2148-2157
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2121376498
- Cited by
- 2,476
- References
- 37
- FWCI
- 115.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.